Drug Profile
Mavorixafor - Sanofi/X4 Pharmaceuticals
Alternative Names: ABSK-081; AMD-070; AMD-11070; X4P 001 RD; X4P-001; X4P-001-IOLatest Information Update: 03 Apr 2024
Price :
$50
*
At a glance
- Originator AnorMED
- Developer Abbisko Therapeutics; X4 Pharmaceuticals
- Class Antineoplastics; Antiretrovirals; Benzimidazoles; Diamines; Hydroquinones; Small molecules
- Mechanism of Action CXCR4 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Waldenstrom's macroglobulinaemia
Highest Development Phases
- Preregistration WHIM syndrome
- Phase II Neutropenia
- Phase I/II Malignant melanoma; Renal cell carcinoma; Triple negative breast cancer
- Phase I Waldenstrom's macroglobulinaemia
- Preclinical Solid tumours
- Discontinued HIV-1 infections
Most Recent Events
- 23 Feb 2024 Efficacy data from a phase III trial in WHIM-syndrome presented at the Annual Meeting of the American Academy of Allergy, Asthma and Immunology (AAAAI-2024)
- 31 Dec 2023 X4 Pharmaceuticals has patents pending for mavorixafor in USA and globally, prior to December 2023
- 31 Dec 2023 X4 Pharmaceuticals has patent protection for mavorixafor, prior to December 2023